同日，叮当健康发布截至2024年6月30日止六个月中期业绩，该集团期内取得收入22.68亿元(人民币，下同)，同比增加0.92%;股东应占亏损8449.1万元，同比收窄24.95%;每股基本亏损0.06元。公告称，总收入的增长主要是由于药品及医疗健康业务收入由截至2023年6月30日止六个月的21.85亿元增加1.2%至截至2024年6月30日止六个月的22.10亿元。Dingdang Health (09886) fell more than 12% and, at the time of publication, fell 12.73% to HKD 0.96, with a turnover of HKD 13.9641 million.
According to the Wise News app, Dingdang Health (09886) fell more than 12% and, at the time of publication, fell 12.73% to HKD 0.96, with a turnover of HKD 13.9641 million.
On August 16th, the Hang Seng Index Company announced the latest quarterly review results, in which Dingdang Health was removed from the Hang Seng Composite SmallCap Index. The change will be implemented after the market closes on September 6, 2024 (Friday) and will take effect from September 9, 2024 (Monday).
On the same day, Dingdang Health released its interim results for the six months ended June 30, 2024. The Group achieved revenue of RMB 2.268 billion, a YoY increase of 0.92%; shareholders' attributable loss was RMB 84.491 million, a YoY decrease of 24.95%; basic loss per share was RMB 0.06. The announcement stated that the growth in total revenue was mainly due to the increase in revenue from pharmaceutical and medical health businesses, from RMB 2.185 billion in the six months ended June 30, 2023, to RMB 2.21 billion in the six months ended June 30, 2024.
